Vanguard owns 11.56M shares (7.38%) of Bio‑Techne
Bio-Techne Corp reports that Vanguard Capital Management beneficially owns 11,559,571 shares of Common Stock, representing 7.38% of the class.
Rhea-AI Filing Summary
Bio-Techne Corp reports that Vanguard Capital Management beneficially owns 11,559,571 shares of Common Stock, representing 7.38% of the class. The filing states Vanguard exercises sole dispositive power over 11,559,571 shares and sole voting power over 1,379,862 shares. The filing attributes ownership to Vanguard Capital Management and affiliated Vanguard entities per SEC Release No. 34-39538.
Positive
- None.
Negative
- None.
Insights
Vanguard holds a meaningful passive stake of 7.38% in Bio-Techne.
Vanguard Capital Management reports beneficial ownership of 11,559,571 shares with sole dispositive power, indicating voting discretion resides partly with Vanguard through a smaller sole voting position of 1,379,862 shares. The filing is a routine Schedule 13G disclosure for an institutional investor.
Implications depend on Vanguard's portfolio decisions; the filing shows current holdings and control descriptors but does not indicate planned transactions or activism.
Key Figures
Key Terms
beneficially owned regulatory
sole dispositive power regulatory
Schedule 13G regulatory
SEC Release No. 34-39538 regulatory
FAQ
What stake does Vanguard Capital Management report in Bio-Techne (TECH)?
Is this a Schedule 13G or an activist Schedule 13D filing for TECH?
Which Vanguard entities are referenced in the filing for Bio-Techne ownership?
When was the Schedule 13G signed for Vanguard's TECH holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.